Cancer Cells Morph Into Healthy

Cancer Cells Morph Into Healthy Tissue

In a groundbreaking advancement, aggressive cancer cells have been successfully transformed into healthy cells, offering a potential new avenue for treating a particularly aggressive type of childhood cancer that affects muscle tissue.

Researchers have achieved a significant feat by prompting rhabdomyosarcoma cells, known for their aggressive nature, to convert into normal muscle cells. This breakthrough has the potential to pave the way for innovative therapies against this devastating disease and could also hold promise for addressing other forms of human cancers.

Christopher Vakoc, a molecular biologist at Cold Spring Harbor Laboratory, explains, “Remarkably, the cells undergo a metamorphosis into muscle cells. The tumor loses all its malignant characteristics. These cells shift from an incessant self-replicating state to cells dedicated to contraction. With their focus entirely on contraction, they are unable to revert to the rapid multiplication state.”

Cancer is not a singular entity; it emerges through the mutation of cells from diverse body parts. Rhabdomyosarcoma, primarily occurring in children and adolescents, originates in skeletal muscle tissues due to aberrant cell mutations and uncontrolled proliferation.

Characterized by its aggressiveness and high fatality rates – with survival rates ranging from 50 to 70 percent for the

intermediate risk group – rhabdomyosarcoma poses considerable challenges in treatment.

One promising treatment avenue is differentiation therapy, which stems from the observation that leukemia cells and undifferentiated stem cells share immature characteristics. Differentiation therapy compels these cells to progress into specific mature cell types.

Cancer Cells Morph Into Healthy
A diagram illustrating the transformation from rhabdomyosarcoma to muscle cells. (Vakoc lab/Cold Spring Harbor Laboratory)

Vakoc and his research team had previously succeeded in reversing cancerous mutations in Ewing sarcoma, another childhood cancer affecting bones. Building on this achievement, they sought to replicate their success with rhabdomyosarcoma, a cancer type where differentiation therapy was deemed to be distant in terms of realization.

Using a genetic screening approach, the researchers pinpointed potential genes capable of driving rhabdomyosarcoma cells to differentiate into muscle cells. The solution was found in a protein named Nuclear transcription factor Y (NF-Y).

Rhabdomyosarcoma cells produce PAX3–FOXO1, a protein that fuels cancer proliferation and sustains its growth. The research team discovered that by deactivating NF-Y, PAX3-FOXO1 becomes inactive, compelling the cells to continue their development and mature into muscle cells devoid of cancerous behavior.

This discovery marks a pivotal advancement in the journey towards differentiation therapy for rhabdomyosarcoma, potentially accelerating the timeline for the development of such treatments.

Furthermore, the researchers believe that their method, proven effective in two distinct sarcoma types, could hold relevance for various other sarcomas and cancer categories. By providing the means to induce the differentiation of cancer cells, this technique equips scientists with valuable tools to explore methods of causing cancer cells to mature into non-malignant states.

Vakoc notes, “Each successful medical breakthrough has its own unique origin story. Research of this nature serves as the fertile ground from which new drugs emerge.”

The findings of this research have been detailed in the Proceedings of the National Academy of Sciences.

Cancer Cells Morph Into Healthy – Latest News

Shekhar Suman is the Co-founder of BioTecNika Info Labs Pvt. Ltd. He is an Entrepreneur, Writer, Public Speaker, and a Motivational Coach. In his career, he has mentored more than 100,000+ students toward success in the Biopharma Industry. He heads the BioTecNika Group, which comprises,, and An avid reader and listener who is passionate about BioSciences. Today Biotecnika is India's largest Biotech Career portal, with over 5 Million subscribers from academia & Industry. It's ranked among the top 50 websites worldwide in the Biology category.